|By NeonDrum News||
|May 26, 2014 11:22 AM EDT||
DNA Electronics Ltd, a provider of point-of-care genomic diagnostics solutions for medical and healthcare applications, today announces the appointment of Dr Steve Allen as Chief Operating Officer, along with the doubling of its development team from 30 to 60 scientists and engineers. The appointment of Dr Allen and the expansion of DNA Electronics' product development capabilities follows the recent investment in the company by the Genting Group. The new funding by existing investor Genting Group will be targeted at developing the Genalysis® genomic diagnostics product line for time-critical point-of-care applications.
Dr Allen is a former Board Member and advisor to Solexa Inc, who developed Illumina's Next Generation Sequencing platform, and has a 25-year track record of leadership in Life Science companies. Dr Allen has overseen the successful launch of more than 50 new scientific product families.
Commenting on his appointment, Dr Allen said: "I am thrilled to be joining DNAe at this exciting point of the company's evolution from R&D and licensing house to a fully-fledged product business, developing solutions that have the potential to save lives and improve the health of people around the world. The next decade will see the power of genomics applied rapidly at the point-of-care and I intend to ensure that DNAe is a leader in this field."
Professor Chris Toumazou, CEO and Founder of DNA Electronics added: "The timing of this key appointment is excellent for DNA Electronics as we now push forward into developing our latest semiconductor-based genomic diagnostic systems. We are absolutely delighted to have an industry executive of Steve's calibre join our management team and lead this new direction.